Elevation Point Wealth Partners LLC Buys New Position in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Elevation Point Wealth Partners LLC bought a new stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 5,063 shares of the company’s stock, valued at approximately $207,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Brown Advisory Inc. grew its stake in Establishment Labs by 23.1% in the fourth quarter. Brown Advisory Inc. now owns 2,338,369 shares of the company’s stock valued at $107,729,000 after purchasing an additional 438,057 shares in the last quarter. Capital Research Global Investors grew its stake in Establishment Labs by 29.3% in the fourth quarter. Capital Research Global Investors now owns 1,911,525 shares of the company’s stock valued at $88,064,000 after purchasing an additional 433,484 shares in the last quarter. Findell Capital Management LLC grew its stake in Establishment Labs by 28.5% in the fourth quarter. Findell Capital Management LLC now owns 1,346,480 shares of the company’s stock valued at $62,032,000 after purchasing an additional 298,380 shares in the last quarter. William Blair Investment Management LLC grew its stake in Establishment Labs by 44.1% in the fourth quarter. William Blair Investment Management LLC now owns 812,825 shares of the company’s stock valued at $37,447,000 after purchasing an additional 248,888 shares in the last quarter. Finally, Bamco Inc. NY grew its stake in Establishment Labs by 53.8% in the fourth quarter. Bamco Inc. NY now owns 752,886 shares of the company’s stock valued at $34,685,000 after purchasing an additional 263,500 shares in the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $48.00 price target on shares of Establishment Labs in a research note on Friday, June 13th. Wall Street Zen upgraded Establishment Labs from a “sell” rating to a “hold” rating in a research note on Saturday. Stephens restated an “overweight” rating and issued a $52.00 price target on shares of Establishment Labs in a research note on Thursday, March 6th. Finally, BTIG Research started coverage on Establishment Labs in a research note on Friday, May 16th. They set a “buy” rating and a $62.00 target price for the company. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $52.40.

Establishment Labs Stock Performance

Shares of NASDAQ ESTA opened at $37.41 on Wednesday. The company has a current ratio of 3.36, a quick ratio of 2.05 and a debt-to-equity ratio of 5.72. Establishment Labs Holdings Inc. has a 12 month low of $26.56 and a 12 month high of $52.41. The stock has a 50 day moving average of $34.28 and a 200-day moving average of $37.19. The company has a market capitalization of $1.08 billion, a P/E ratio of -12.07 and a beta of 0.74.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.13. The business had revenue of $41.38 million during the quarter, compared to the consensus estimate of $41.15 million. Establishment Labs had a negative return on equity of 196.25% and a negative net margin of 52.34%. The firm’s quarterly revenue was up 11.3% on a year-over-year basis. During the same period in the previous year, the company posted ($0.58) EPS. As a group, equities research analysts predict that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Establishment Labs Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.